Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
AN2 Therapeutics, Inc. (ANTX) had Consolidated Net Income/Loss of $-10.03M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
$-10.03M |
|
-- |
|
-- |
|
$10.55M |
|
$-10.55M |
|
$0.52M |
|
$-10.03M |
|
$-10.03M |
|
$-10.03M |
|
$-10.03M |
|
|
Consolidated Net Income/Loss |
$-10.03M |
$-10.03M |
|
$-10.55M |
|
$-10.63M |
|
34.06M |
|
34.06M |
|
$-0.29 |
|
$-0.29 |
|
| Balance Sheet Financials | |
$87.49M |
|
-- |
|
-- |
|
$87.49M |
|
$5.56M |
|
-- |
|
$0.17M |
|
$5.73M |
|
$81.76M |
|
$81.76M |
|
$81.76M |
|
35.99M |
|
| Cash Flow Statement Financials | |
$-12.07M |
|
$8.29M |
|
$37.33M |
|
$19.94M |
|
$53.49M |
|
$33.55M |
|
$1.46M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
15.73 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-12.07M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-12.27% |
|
-12.27% |
|
-11.46% |
|
-12.27% |
|
$2.27 |
|
$-0.35 |
|
$-0.35 |
|